TrialBreast (Edinburgh, Scotland)2020

First-line bevacizumab and eribulin combination therapy for HER2-negative metastatic breast cancer: Efficacy and safety in the GINECO phase II ESMERALDA study.

Anne-Claire Hardy-Bessard et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.